BlackRock Institutional Trust
ARCT icon

BlackRock Institutional Trust’s Arcturus Therapeutics ARCT Stock Holding History

BlackRock Institutional Trust’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-45
Closed -$6K – 3949
2013
Q4 		$6K Buy
+45
New +$5.66K ﹤0.01% 3940

Other funds holding ARCT

JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $214M AUM 62.74% 1-Year Est. Return
AWMDMG
Austin W. Marxe & David M. Greenhouse New York $733M AUM 21.72% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
SC
Sophrosyne Capital New York $11.5M AUM 17.82% 1-Year Est. Return
ACPU
Arrowgrass Capital Partners (US) Dover, Delaware $380M AUM 20.87% 1-Year Est. Return
TMC
Trellus Management Company Delray Beach, Florida $72.8M AUM 4.5% 1-Year Est. Return
Bailard
Bailard Foster City, California $4.94B AUM 25.15% 1-Year Est. Return
Baker Avenue Asset Management
Baker Avenue Asset Management San Francisco, California $5.28B AUM 39.19% 1-Year Est. Return

BlackRock Institutional Trust's ARCT Position: Q1 2014 in Review

BlackRock Institutional Trust sold out of Arcturus Therapeutics (ARCT) in Q1 2014, closing a stake of 45 shares — an estimated $6K sold.

BlackRock Institutional Trust first reported a position in ARCT in Q4 2013 and held it in 1 quarter. The position peaked at $6K in Q4 2013. 24 funds tracked by Wall St. Rank hold ARCT as of Q1 2014.

  • BlackRock Institutional Trust reported no remaining Arcturus Therapeutics position as of Q1 2014 after selling out during the quarter.
  • BlackRock Institutional Trust sold 45 Arcturus Therapeutics shares in Q1 2014, an estimated $6K.
  • BlackRock Institutional Trust first reported a position in Arcturus Therapeutics in Q4 2013 and held it in 1 quarter.
  • BlackRock Institutional Trust's Arcturus Therapeutics position peaked at $6K in Q4 2013.
  • 24 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2014.

Based on BlackRock Institutional Trust's 13F filing for Q1 2014, filed 2 May 2014.